Antibody-Drug Conjugate for Advanced HER2-Positive Gastric Cancer Improves Outcomes
T-DXd treatment was associated with a better ORR and prolonged OS compared with standard chemotherapy with either irinotecan or paclitaxel.
Gastrointestinal Cancer
Single, Priming Dose of Tremelimumab Plus Durvalumab Active in Second-Line Hepatocellular Carcinoma
Trememlimumab thought to induce immune response.
Third-Line Trastuzumab Deruxtecan May Be Effective in Certain Patients With HER2-Positive Metastatic CRC
Antibody-drug conjugate trastuzumab deruxtecan demonstrated promising efficacy against relapsed, metastatic, HER2+ CRC according to results from a phase 2 trial.
First-Line Donafenib May Be Superior to Standard of Care in Advanced Hepatocellular Carcinoma
A phase 2/3 trial found that patients with advanced HCC who received donafenib had significantly longer OS compared with sorafenib, the standard first-line therapy.
3 Years of Adjuvant Imatinib Improves Long-Term Overall Survival in Gastrointestinal Stromal Tumor
Adjuvant treatment of GIST with imatinib for 36 months prolonged OS and RFS compared with 12 months of imatinib, according to data from nearly 10 years of follow-up.
Weight Loss Following Chemotherapy Was Associated With Worse Outcomes in Patients With Advanced Gastric Cancer
These study findings show that weight loss occurred early among patients with advanced gastric cancer and was associated with shorter overall survival.
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Survival Benefit Seen With Atezolizumab-Bevacizumab Combo in Unresectable HCC
The combination resulted in durable response in many patients.
Qinlock Approved As Fourth-Line Treatment of Advanced GI Stromal Tumors
The FDA has approved Qinlock™ (ripretinib; Deciphera) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Next post in General Oncology
